Life SciencesLiability
Contact

TL;DR

Five clinical trial insurance program structures for 2026 - sized by phase (first-in-human, Phase 1, Phase 2 multi-site, Phase 3 with EU sites, investigator-sponsored trials, gene therapy / cell therapy with long-term follow-up). The 2026 standard sizes CTL per trial rather than per sponsor, places EU CTR compliance before site activation, and explicitly funds the sponsor's CTA contractual indemnity to investigators and sites.

Best of 2026

Best Clinical Trial Insurance Programs 2026.

Clinical trial insurance (clinical trial liability, or CTL) sizing follows trial phase AND indication AND geographic scope. The five program structures below cover the typical sponsor and investigator landscape - from first-in-human Phase 1 through Phase 3 multi-country trials, investigator-sponsored ISTs at academic medical centers, and gene therapy / cell therapy programs with FDA-mandated long-term follow-up. Each includes the load-bearing coverages, regulatory expectations, and premium ranges.

  1. 01

    First-in-human / Phase 1 sponsor

    Biotech sponsors dosing healthy volunteers or small patient cohorts. Single-site or limited multi-site. Novel mechanism.

    • - $5M-$10M per-trial clinical trial liability baseline; first-in-human dosing of biologics, gene therapies, or irreversible interventions push to $10M-$25M.
    • - Defense costs outside the limit (specialty CTL standard, not generic E&O).
    • - Subject-injury / no-fault compensation extension funding the sponsor's CTA contractual obligation to investigators and sites.
    • - Sponsor named as the policyholder; CRO and investigator-sponsor coverage flows through additional insured endorsements.
    • - Claims-made form with extended reporting period (ERP) at trial close-out for long-latency indications.

    Premium range: $25K-$100K per trial annually depending on indication and intervention type.

  2. 02

    Phase 2 multi-site sponsor

    Biotech sponsors running larger patient cohorts (50-300 subjects) across multiple sites. Typically Series A through Series C funded.

    • - $5M-$10M per-trial baseline; oncology and rare disease cohorts often $10M-$15M.
    • - IRB and central IRB liability coverage where the trial uses a central IRB rather than site-specific IRBs.
    • - Investigator-sponsor coverage flows through named additional insured on each site's site-level CTL plus sponsor-side backstop coverage.
    • - Regulatory defense scope for FDA Bioresearch Monitoring (BIMO) program inquiries triggered by trial events.
    • - Cyber coordination with the sponsor program for CRO and EDC vendor breach scenarios affecting trial data.

    Premium range: $40K-$200K per trial annually.

  3. 03

    Phase 3 sponsor with EU sites

    Sponsors running large registration-enabling Phase 3 trials with EU member-state sites under the EU Clinical Trials Regulation (CTR).

    • - $10M-$25M per-trial sponsor-side CTL; pivotal oncology or gene therapy trials push to $25M+.
    • - EU CTR endorsement with country-specific compliance documentation - either local-admitted policies issued by EU member-state-licensed carriers or a master policy with country-specific endorsements.
    • - Real-time site activation coverage - documentation must be in place before EU site IRB / ethics committee approval, not after.
    • - Coordination with sponsor pharmacovigilance and regulatory defense scope for parallel FDA / EMA / national-competent-authority inquiries.
    • - Reps & warranties coverage where the sponsor program intersects with a transactional event (asset purchase, partnership, BLA submission).

    Premium range: $150K-$600K+ per trial annually depending on EU site count and indication.

  4. 04

    Investigator-sponsored trial (IST) at academic medical center

    Academic medical center investigator holding the IND. Industry-funded or NIH-funded protocols. Multi-center expansion common.

    • - $3M-$10M coordinated three-layer structure: AMC self-insurance trust (covers AMC investigator and AMC sites), standalone CTL with IST investigator as named insured (covers external sites and multi-center coordination), and industry sponsor backstop layer where applicable.
    • - External-site coverage placed as standalone CTL when the AMC self-insurance does not extend to private practices, community hospitals, or other AMCs in the protocol.
    • - Industry sponsor backstop indemnity layer triggered when the trial is industry-funded and the sponsor provides supplementary support.
    • - Coordination across the three layers - claim notification, defense coordination, and indemnity allocation - documented in the placement structure.
    • - Tail / ERP coverage at close-out, sized to the indication (gene therapy more expensive than oncology, oncology more expensive than cardiovascular).

    Premium range: $30K-$150K annually for the standalone layer; AMC self-insurance and industry backstop costs sit elsewhere.

  5. 05

    Gene therapy or cell therapy sponsor (any phase, with long-term follow-up)

    Sponsors developing gene therapy, cell therapy, or other irreversible interventions with FDA-mandated long-term follow-up requirements (typically 10-15 years).

    • - $10M-$25M per-trial CTL; pivotal Phase 3 dosing in oncology gene therapy often $25M+.
    • - Long-term follow-up registry coverage extending claim-reporting window to match the FDA-mandated follow-up period (10-15 years).
    • - Extended reporting period (ERP) endorsement purchased at trial close-out is non-discretionary - subject injury claims surface 5-15 years after dosing.
    • - Coordination with eventual products liability tower at commercial launch - the CTL and products policies should be written by carriers with appetite for both and form depth that prevents coverage gaps at the trial-to-commercial transition.
    • - Regulatory defense scope covering FDA, CBER (Center for Biologics Evaluation and Research), and EMA scientific advice inquiries.

    Premium range: $100K-$500K+ per trial annually depending on indication, scale, and follow-up duration.

Frequently asked

Common questions about clinical trial insurance

What is the best clinical trial insurance program structure?

The best program structure depends on phase, site count, geography, indication, and sponsor type. First-in-human and Phase 1 sponsors baseline at $5M-$10M per trial. Phase 2 multi-site sponsors at $5M-$10M with oncology/rare disease at $10M-$15M. Phase 3 with EU sites at $10M-$25M+ with mandatory EU CTR compliance. IST at AMC: three-layer coordinated structure across AMC self-insurance, standalone CTL, and industry backstop. Gene therapy / cell therapy at any phase: long-term follow-up registry coverage and extended reporting period at close-out.

How much does the best clinical trial insurance cost?

Premium ranges by structure: first-in-human / Phase 1 $25K-$100K per trial; Phase 2 multi-site $40K-$200K; Phase 3 with EU sites $150K-$600K+; IST standalone layer $30K-$150K; gene therapy / cell therapy with long-term follow-up $100K-$500K+. Cost drivers: indication severity, intervention reversibility, EU CTR compliance scope, prior incident history, sponsor financial stability, and long-term follow-up duration.

Who provides the best clinical trial insurance?

The clinical trial liability market is a narrow specialty - a handful of carriers globally write the bulk of large-scale CTL with EU CTR capability. Specialty life-sciences underwriters at admitted carriers and Lloyd's-backed surplus-lines paper cover most of the US market. The best carrier for a specific sponsor depends on indication, phase, geography, and the sponsor's broader program structure. A specialty broker accesses the right carrier panel rather than placing through generalist commercial markets.

How does sponsor-CRO clinical trial insurance coordination work?

Best-practice structure: sponsor places per-trial CTL (covers subject injury arising from protocol intervention); CRO maintains professional liability and E&O sized to monitoring scope (covers monitoring errors and protocol-deviation reporting failures); both parties are named as additional insureds on the appropriate policy. CTA and MSA should include explicit boundary language defining which party places which coverage. Where the sponsor refuses to take CTL, the CRO needs sponsor backstop indemnity plus CTL coverage purchased on the sponsor's behalf with the CRO as named insured.

What clinical trial insurance is required for EU sites?

The EU Clinical Trials Regulation (No 536/2014) requires sponsors to maintain insurance or indemnification covering trial sites and subjects in every EU member state where a study is conducted. The form, limits, and admitted-paper requirements vary by country. Compliance is non-discretionary - documentation must be in place before EU site IRB / ethics committee approval. The placement is typically either local-admitted policies issued by carriers licensed in each member state or a master policy with country-specific endorsements. Some sponsors place this directly; others place through a global carrier network.

Why does gene therapy clinical trial insurance need long-term follow-up?

FDA-mandated long-term follow-up requirements for gene therapy programs (typically 10-15 years post-dosing) create a unique claim-tail challenge. Subject injury claims from gene therapy interventions can surface years or decades after dosing - the underlying claims-made CTL form is structurally inadequate without long-term follow-up registry coverage and an extended reporting period endorsement purchased at trial close-out. Cell therapy programs face similar (sometimes shorter) follow-up obligations. Gene therapy CTL is materially more expensive than other indications because of this structural long-tail.

Clinical trial insurance practice page →CRO insurance practice →Biotech insurance practice →Clinical trial liability calculator →CTL for investigator-sponsors →

Clinical trial coverage review

A specialist will reach out by end of business day.

Request a coverage review